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The use of nanomaterials in medicine has grown very rapidly, leading to a concern about
possible health risks. Surely, the application of nanotechnology in medicine has many
significant potentialities as it can improve human health in at least three different ways: by
contributing to early disease diagnosis, improved treatment outcomes and containment
of health care costs. However, toxicology or safety assessment is an integral part of any
new medical technology and the nanotechnologies are no exception. The principle aim
of nanosafety studies in this frame is to enable safer design of nanomedicines. The most
urgent need is finding and validating novel approaches able to extrapolate acute in vitro
results for the prediction of chronic in vivo effects and to this purpose a few European
initiatives have been launched. While a “safe-by-design” process may be considered as
utopic, “safer-by-design” is probably a reachable goal in the field of nanomedicine.
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INTRODUCTION
Nanomedicine encloses many potential promises, ranging from optimized, targeted, and even
personalized treatments with decreased toxicity, to very sensitive, and cheaper diagnostic
approaches with contained costs, innovative functionalized biomaterials, and the prospect of
cellular and tissue regeneration strategies (Wagner et al., 2006; Senjen, 2013).
Nanotechnology-based approaches have already been translated into highly accurate and
sensitive diagnostic tests, most prominent of which is the early detection of neoplastic disease
(Ferrari et al., 2009), targeted therapeutic interventions, following the statement that “targeted
delivery will revolutionize disease treatment” (Duncan and Gaspar, 2011) and theranostic
applications, having the possibility to combine in the same disease intervention both diagnosis
(through imaging) and treatment (through thermal ablation) (Lammers et al., 2011).
Nanotechnological devices used in nanomedicine possess unique properties, not found in
identical devices of smaller or larger dimensions, as they stem from their nanoscale dimension
(Ferrari et al., 2009). However, a consensus has not been reached yet as for a scientific definition
of “nanoparticle” (NP) (Satalkar et al., 2016) and as a consequence slightly different size limit
definitions are applied in different fields of nanotechnology (Schütz et al., 2013).
In this review we first summarize the current state regarding safety evaluation of nano-based
therapeutics and then we focus on the growing need for nanosafety studies for safer design of
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nanomedicines, including the employment of novel acute in vitro
studies to extrapolate chronic effects that occur in vivo.
RISK ASSESSMENT AND RISK
MINIMIZATION IN NANOMEDICINE
The implementation of nanotechnology in medicine is a process
that has occurred rapidly, suddenly moving from basic research
and laboratory experimentation to clinical trials (Kola and
Landis, 2004; Etheridge et al., 2013; Hafner et al., 2014).
Many nanomedicine formulations have already entered the
market. A recent study identified 247 nanomedicine applications
and products, a very significant number, approved for or
nearing in-human use (Etheridge et al., 2013) and it has
been envisioned that the worldwide nanomedicine market
may double by 2019 (BBCResearch, 2015). In the majority
of cases, these artifacts are nanoformulations of current
or novel drugs (58%) or nanobiomaterials (25%); however,
nanotechnology has the potential to add innovative functionality
to many pharmaceutical products and medical devices (Wagner
et al., 2006). As for the regulatory aspects, it remains to
be determined if nanomedicines fall into the category of
medicinal products or medical devices. EU legislation makes
clear distinction between the two, resulting in different regulatory
approaches for risk assessment of medicinal products and
medical devices. In the case of medicinal products, suitable
clinical trials have to be performed prior to provision of a
preliminary market authorisation for human use (Directive
2001/83/EC), while in the case of medical device market
introduction requires lesser degrees of testing that can vary
on the basis of the risk category the device falls into
[Directive 2007/47/EC currently under revision: COM (2012) 542
final].
An elevated degree of unpredictability about prospective
hazards and true advantages of NPs and nanomedicines,
however, created remarkable obstacles along this translational
pathway (Resnik and Tinkle, 2007). As such, nanotechnological
approaches have opened up a few issues with respect to
their proper risk assessment and risk minimization (Hogle,
2012), with particular emphasis on human and environmental
toxicity (Allhoff, 2009; Ramachandran et al., 2012). Especially
compelling in this respect are “first in human” (FIH) trials of
nanotechnology medical applications, as they raise the highest
degree of unpredictability in all clinical area (Kimmelman and
John London, 2011). Especially important for FIH nanomedicine
trials is the explicit description of the study purposes within
the consent form. Today, the primary and sometimes exclusive
aim of FIH trials is safety (King, 2012), even though innovative
technologies like nanomedicines do not always fit the classical
clinical trial phases that are followed when a new drug is
developed. Thus, the information contained in the consent
form should focus on these purposes and emphasize all
aspects related to safety testing and risk identification (King,
2012).
Research in the field of nanomaterials (NMs) applied to
medicine has continued to grow upon time, but it has been
primarily focused around technological improvement, and
not directed toward the definition of the potential risks of
nanoproducts, thus nanosafety is an area that has remained
poorly assessed. The fate of a nanomaterial upon entrance in the
organism, whether it will be accumulated and become toxic, or
rendered available at a biological level and transformed, or if and
how it will interact with cells andmacromolecules inside cells, are
all crucial aspects that need to be understood. The conventional
approaches listed in current test guidelines are not very likely to
turn out as appropriate for the assessment of nanomedicine risks,
rendering it urgent to develop NM-specific standards, guidelines,
and tools. It is well-known, in fact, that often the bulk materials
behave different in the nanometer regime and there is the
need of generally accepted test methods for the characterization
of nanomaterials. The methods currently existing can be not
at all suitable to characterize nanomaterials for their specific
properties. For example, when nanoparticles are dispersed
in water, air or biological media they show a tendency to
agglomerate and can even lose their nano-dimension. For this, it
is important a careful andwidemorphological, physico-chemical,
and in vitro and in vivo biological characterization not only on
the manufactured nanomaterials but also on nanomaterials after
contact with relevant media. The evaluation of the effects of
dispersion methods and of molecular interaction with biological
components, cells and tissues on properties of nanomaterials
represent a fundamental step for an effective control of
nanomaterial risk. The degradation of the nanomaterials in the
biological environment, the release of molecules or debris and the
functionalization with organic substances could induce cytotoxic
effects to be explored using methods already employed and
validated in nanotoxicology but also improving the physico-
chemical characterization. QualityNano (www.qualitynano.eu;
finished in 2015) has represented one of the first European
initiatives along this line. It was an analytical research
infrastructure addressing quality in NM safety assessment,
through driving reliable and reproducible approaches to
nanometrology and NM characterization before, during and
after exposure to living systems. It included the development of
standard operating protocols (SOPs) for analysis of the possible
risks posed by NMs, focusing on assay reproducibility, use of
appropriate positive and negative controls and controlling dose
delivered to living systems (Senjen, 2013).
Assessment and management of risks, as well as risk
communication are among the most challenging issues for
nanomedicine clinical research (Resnik and Tinkle, 2007).
Surely, our understanding and knowledge of different
nanosized materials can be improved by single in vivo
animal experiments and ex vivo laboratory testing, yet
when a new nanomedicine product is to be tested in Phase
I clinical trial they are not sufficient to resolve all of the
uncertainty surrounding the first exposure of a human
subject. What can be ethically accepted is that the risks
potentially posed to human subjects by the new therapy are
reasonable in relation to the new therapy potential benefits
and, from a regulatory standpoint, that risks to the subject
and society are minimized, wherever possible (Emanuel et al.,
2000).
Frontiers in Pharmacology | www.frontiersin.org 2 March 2018 | Volume 9 | Article 228
Accomasso et al. Nanomedicine Risk Assessment and Minimization
PREDICTIVE TOXICOLOGICAL
APPROACHES, ALTERNATIVE TEST
STRATEGIES, AND 3RS APPROACHES
Extensive preclinical and clinical testing is needed prior to
application of nanomedicine products in the three relevant areas
of diagnosis, prevention, and treatment of disease, yet many
aspects of NMs, including their toxicological, pharmacological,
and immunological properties, have entered the scientific
exploration only recently. Early safety studies are exceedingly
needed to define whether the risk to benefit displayed by a
specific nanomedicine is acceptable for the proposed use, thus
determining if that nanotechnology will have the promise for
further development in a clinical application (Duncan and
Gaspar, 2011). Importantly, traditional approaches to toxicology,
which are inherently descriptive in nature, will need to shift to
predictive toxicology and this shift ascribes to both chemicals in
general and NMs in particular (Oberdorster, 2010).
• Predictive toxicology is based on mechanism-based
approaches relying on high-throughput screening (HTS)
techniques. (i) The starting point is the generation of
in vitro toxicity data resulting from the application of
multiparametric, automated screening procedures. This in
vitro phase of work may predict the possibility for disease
or other pathological outcomes in vivo, based on the specific
physicochemical properties of engineered NMs that are
described (Nel et al., 2013b). (ii) The in vivo step will first
of all validate the HTS techniques and will then improve
them by establishing clear structure activity relationships. (iii)
Then heat maps are developed on the basis of normalized
data set, and self-organizing map features are exploited
to organize all these information. (iv) Finally, appropriate
combinations of both in vitro and in vivo approaches can be
defined, with the final goal to establish hazard ranking and
modeling. The landmark 2007 report from the US National
Academy of Sciences, “Toxicity Testing in the Twenty-first
Century: A Vision and a Strategy” (http://www.nap.edu/
catalog.php?record_id=11970) is in agreement with this
operation modality, clearly defining that a transition from
qualitative laboratory testing and descriptive animal studies to
mechanistic, quantitative testing funded on the employment
of human cell types and high-throughput approaches will
dramatically increase efficiency of toxicity evaluation (Nel
et al., 2013b). Hazard assessment of large numbers of NMs can
in this way be performed using pathways of toxicity (POTs),
consisting in mechanism-based testing and representing the
aim of the predictive toxicology approach (Nel, 2013). For
the successful implementation of this methodology, careful
selection of HTS techniques to be used in vitro as well as of
POTs designed at the cellular level is needed, in order for
them to reflect as many as possible pathogenic effects at the
organism level. Although many methods and protocols were
developed and validated for a predictive risk assessment of
NMs, more work is needed regarding both physicochemical
properties of NMs and their interaction with biological
media. For example, the surface chemistry of the particles
should be evaluated with particular attention considering that
dissolution/dispersion and fate of NMs in biological media
are affected by particle surface, surface charge, and radical
formation potential.
• Use of alternative test strategies (ATS), aimed at reducing
the number of animal testing by widening the employment
of in vitro and in silico strategies, represents a promising
new toxicological paradigm for NMs in medicine (Nel, 2013).
Existing and emerging methods used as part of an ATS are
presented in Table 1. HTS techniques, high-content screening,
and computational modeling are all important resources for
ATS, having the potentiality to analyse in a comparative way
manyNMs simultaneously (Nel, 2013). Further, the use of ATS
approach allows for multiple hazard assessment steps during
the entire process of product development and provides large
enough amounts of data to reduce the number of animals used
by prioritizing testing at each of the incremental assessment
stages described above (Nel et al., 2013a). As a matter of
fact, numerous challenges still need to be faced prior to
complete acceptance of ATS. For example, cellular HTS is
still limited when a chronic disease condition is to be studied
through predictive toxicological approaches, because currently
in vitro cultured cells cannot recapitulate the chronology of
the multistep process leading to a chronic disease at the organ
or systemic level (Leist and Hartung, 2013). It is also not
always easy to discriminate between end-points that disclose
adverse outcomes, or that may conduct to adverse outcomes
later on, and those that reflect non-adverse outcomes (Slikker
et al., 2004). For regulatory purposes, risk assessment or risk
management based on the use of ATS to replace for animal
testing is not yet at the level of general acceptance. However,
the potential utility of ATS approaches to investigate NM
hazard is not under discussion and there is a general agreement
about the application of ATS approaches to prioritize NMs
for further subsequent toxicity testing and risk assessment
prior to or upon product development (Nel et al., 2013a).
Future strategies should include refinement of existing tests,
such as development of organotypic 3D co-cultures, use of
primary cells or stem-cell-derived systems and expansion of
endpoints (i.e., carcinogenicity for chronic exposure) and their
simultaneous testing. In addition, there is a need to predict
the distribution, translocation, and bioaccumulation of NMs
throughout the human body after exposure: pharmacokinetic
(PBPK) models already developed in animal for specific NM
are expected to be extrapolated also to humans. Finally, a
comparison between in vitro and in vivo tests and long-term
evaluation should be carefully considered.
• Reduction of in vivo experiments through the employment
of alternative testing approaches is in agreement with
the 3Rs rule (refine, reduce, and replace animal testing).
There is an opportunity to improve regulatory toxicology
by first optimizing the use of the entire amount of
existing information concerning groups of structurally similar
materials, by second gaining information from in vitro and
in silico experimental approaches, and finally conducting
targeted animal testing only when necessary (Hartung, 2009).
Ideally, these types of strategies should encompass decision
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TABLE 1 | Existing and emerging methods used as part of an ATS for NM evaluation.
Test type Aim Key stages or assay Limitation Ref
Genotoxicity Rapid measurement of DNA damage,
chromosomal damage; detection of
upregulated DNA damage signaling
pathways
- MN (Micronucleus assay)
- CometChip Platform
- γ-H2AX assay
- FADU (Fluorimetric Detection of
Alkaline DNA Unwinding) assay
- ToxTracker reporter assay
Many factors can artificially influence
assay results, as material and
environment
Nelson et al., 2017
QSAR (Quantitative
Structure Activity
Relationships)
Prediction of nanomaterial
exposure-dose-response
Steps of data assembling, structure
characterization, model construction,
model evaluation, and lastly
interpretation of mechanisms
Small number of data sets Winkler, 2016
SSDs (species
sensitivity distributions)
Estimation of the maximum
acceptable concentrations of
chemicals in environmental risk
assessment
Computational approaches Few data known Chen et al., 2017
Band gap analysis Prediction of toxic potential using
metal oxide conduction band energy
levels
In vitro toxicological effect related to
conduction energy and metal
dissolution
Limited to metal based nanomaterials Zhang et al., 2012
Cytotoxicity Screening of nanomaterial-induced
cytotoxicity
- Cellular metabolic activity
- Oxidative stress
- Apoptosis
- Cell membrane integrity
- Impedance based integrity
Time-consuming, labor-intensive,
complex, and in some instances
unreliable owing to NM interferences
Cimpan et al.,
2013; Guadagnini
et al., 2015;
Accomasso et al.,
2016
OMICS Identification of new pathways and
mechanisms in nanotoxicity not
visible in conventional testing
1.1.1 Epigenomics—miRNomics
1.1.2 Epigenomics—DNA methylation
and histone modification
1.1.3 Transcriptomics
1.1.4 Proteomics
1.1.5 Metabolomics
Request for high sample quality
(freezing, protection against
degradation)
Lack of standardization of sample
preparation
Predictive value of the omics
techniques not entirely clear
Fröhlich, 2017
High-content analysis Capacity for monitoring a range of
morphometric, functional, and
biochemical properties of cells
Simultaneous identification of different
parameters using fluorescence
Possible fluorescence-dye toxicity
Limitation in adequate cell line
Brayden et al.,
2015
points that depend on ad interim results and a critical aspect
of the validation process becomes a correlation between in
vitro and in silico with in vivo results. From an ethical and
economical perspective it is not acceptable to test each NM in
animals, thus a triage step based on an in vitro screening of
these materials is necessary. Efforts in this direction are being
made in the USA (Nel, 2013), but also in Europe collaborative
initiatives are being created to increase open conveyance
and sharing of results between different research groups.
Overall, testing programme for regulatory purpose addressed
a series of physico-chemical endpoints including methods
and assays for a list of manufactured NMs, mostly inorganic
carbon and metal oxide NMs (TiO2, SiO2, ZnO, CeO2). For
different physico-chemical endpoints, several methods were
used to evaluate: chemical composition (assay: EDX, ICP-OES
ICP-MS, CHN elemental analysis), size [assay: DLS, TEM,
SEM, AFM, (U)SAXS), WAXS], shape (TEM), coating (XPS,
STEM-EDS, FTIR analysis of functional groups), surface area
(VSSA, SAXS), Water solubility/dispersibility, cristallite size
(XRD) (Rasmussen et al., 2018). In vitro studies addressed
cytotoxicity, immunotoxicity, and genotoxicity testing using
different cell culture models (i.e., blood, lung, placenta,
brain, liver, gastrointestinal system) according to harmonized
protocols.
The NanoTEST project (http://www.nanotest-fp7.eu/;
finished in 2012) was one of the first examples. Many
efforts were put in defining appropriate standard protocols,
whose frequent lack represented an important problem
experienced in testing NP potential hazards before clinical
application (Juillerat-Jeanneret et al., 2015). A representative
selection of commercial NMs currently or soon-to-be-applied
in human medicine was investigated. To identify relevant
short-term hazard models, the project used several standard
toxicity assays for different markers such as cell viability,
pro inflammatory response, oxidative stress, genotoxicity,
immunotoxicity, cell uptake, and transport. Upon completion
of the study, indications for full appraisal of NP toxicity
included a few cytotoxicity measurements, a set of 2–3
representative cell types and five NP concentrations (Dusinska
et al., 2015). NANoREG (www.nanoreg.eu; finished in 2017),
FutureNanoNeeds (www.futurenanoneeds.eu; finished in 2017),
and the ongoing NanoReg2 (www.nanoreg2.eu) are three other
European projects aimed at defining a customary European
strategy to the regulatory testing of fabricated NMs and at
evolving an innovative frame to allow proper classification,
better naming as well as hazard and environmental impact
assessment of the future NMs before their extensive industrial
employment.
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APPLICATION OF ALTERNATIVE TEST
STRATEGIES TO RISK ASSESSMENT AND
MINIMIZATION IN NANOMEDICINE
A number of different nano-specific, well-designed ATS are
under development having the potentiality to provide answers to
focused NM toxicity questions (Shatkin and Ong, 2016).
When the NMunder study has an unknown toxicity, adoption
of aWeight of Evidence (WoE) approach can be considered. Risk
assessment is determined following careful hazard identification
and prioritization taking into consideration and weighting
all in vitro data available, both qualitative and quantitative,
even in the absence of animal data. WoE mainly represents
a methodological approach, where a collection of studies is
analyzed based on expert opinions, systematic reviews or meta-
analyses. When possible, quantitative WoE evaluations are also
applied (Hristozov et al., 2014), for instance for prioritizing
the riskiest occupational exposure scenarios that, in the case
of NMs, can include processing methods, handling methods,
length of time of exposure, protective equipment. They will be all
considered and weighted accordingly, on the basis of quantitative
data and expert judgement. Multiple techniques to test one end
point should be applied to generate data with a high enough
quality to allow for regulatory decisions to be taken based on
WoE approaches.
Intelligent/Integrated Testing Strategies (ITS) are applied for
the identification and prioritization of nanosafety research needs
(Stone et al., 2014). Through this method, hypothesis-driven
questions put to make risk decisions are answered by combining
existing data, available analytical tools, experimental tests where
the main goal is to avoid the need to test each developed NM.
This strategy has been applied to accelerate the risk assessment
process for materials of concern (Jaworska and Hoffmann, 2010)
and benefits include reduced testing, consequently lowering the
costs and limiting animal use; possibility to categorize NMs
by (potential) mechanisms of action; applicability to a large
assortment of testing strategies. Generally, ITS is based on of a
stepped framework beginning with (i) an evaluation of existing
data, that are organized using implements such as adverse
outcome pathways (see below); (ii) measurement of chemical
properties; (iii) biokinetic study of the NM; (iv) choice of suitable
toxicity tests; and (v) employment of a WoE analysis that takes
in consideration all the above results. Refinement steps can
follow concerning both strategy and methods after which WoE
is reevaluated (Oomen et al., 2014).
Conceptual frameworks such as adverse outcome pathways
(AOP) are also been developed. Risk assessment is here
performed through a sequential chain of events that are all
causally linked and lead to an adverse outcome. Based on existing
data, an initial molecular event is described and linked to a series
of downstream key events acting at different biological levels
(organism-cell-molecule) and eventually leading to the adverse
outcome (Ankley et al., 2010).
All the above-mentioned approaches are needed in order
to enable alignment of nanotoxicology with the 3Rs (Burden
et al., 2017). The first step, establishment of a regulatory
framework to enable implementation of alternative non-animal
methods into risk assessment and acceptance, can benefit
from WoE approaches to consider all available evidence from
different non-animal methods. This will increase regulatory
confidence in results from non-traditional methods, via
guidelines and appropriate training, and will support risk
assessors to understand the relevance and applicability of in vitro
data for risk assessment and to adopt a rationale to deal with
uncertainties and limitations inherent to experimental models
(both in vitro and in vivo). The subsequent hazard prediction
step will rely on ITS and adoption of a dual approach: hypothesis
driven studies which test if a particular nanomaterial property
impacts on toxicity, and studies which compare the toxicity of
panels of nanomaterials. These parallel approaches will aim to
accurately identify which NM properties confer toxicity and
to establish a “reference data” for different endpoints for NMs
which are deemed “representative” (dependent on the NM being
studied) and the use of appropriate positive controls to relate the
effects in vitro/in vivo. This involves ensuring that knowledge
already in existence in other areas of toxicology is utilized to
build knowledge within the discipline of nanotoxicology. After
a validation step, AOPs frameworks can be exploited to adapt
current standard in vitro approaches and to improve test item
preparation, dosing, and understanding of toxicity mechanisms.
A rational design of the nanomaterials from the early
phase of material selection, production method optimization,
and product purification has to be considered of fundamental
importance to prevent the safety issues of nanomaterial and
increase their applicative potential. The concept of safer-by-
design emphasizes the importance of the contribution of more
scientists such as engineers, chemists, physicians, and biologists
to contrast the challenges of nanomaterials and satisfy the needs
of the EU to regulate manufactured nanomaterials. The use
of advanced analytical techniques (i.e., ICP, AFM, Chemical
Imaging, biomarker detection) or their combination for the study
of interactions between nanomaterials-relevant media in parallel
with a better control of the preparation process will likely open
up new scenarios in nanotoxicology testing (Dusinska et al., 2017;
Oomen et al., 2018).
CONCLUSIONS AND REMARKS
In nanomedicine, a proper risk evaluation in relation to health
is unavoidable, in order to safeguard societal, ethical and
regulatory acceptance, and public confidence. However, the
individual testing approaches are limited and have turned out
to be inadequate for nanotoxicology evaluations, thus risk
assessment has needed to evolve to accommodate predictive
toxicological analyses and ATS. The main short- to medium-
term objectives should include an improved comprehension
of processes of interaction of NMs utilized in nanomedicine
with organs, tissues, and cells and a clear strategy to tackle
critical topics connecting to toxicity assessment specifically
with respect to alternatives to tests on animals. Among the
most compelling future objectives will be the need to test
nanomedicines not only in healthy physiological environments,
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but also in disease environments that may alter biological
responses and impact safety; in addition, to test nanoparticles
not only individually but within complex mixtures, considering
that nanoparticle incorporation into a variety of already
utilized medical applications are likely to alter their risk
profiles.
A safer-by-design concept has become increasingly important
in risk assessment and minimization of nanomedicines, with
the idea of integrating knowledge of NMs’ potential adverse
effects into the process of designing nanoproducts. This entails
that nanomedicine safety is to be considered as an integrated
route from the very first phases of research and innovation to
the last phases of product validation, clearly different from the
classical safety evaluation paradigm seeking to address potential
concerns and to regulate NMs downstream, close to full product
development, and market entrance.
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